title: Early but not lasting improvement of recalcitrant subcorneal pustular dermatosis (Sneddon-Wilkinson disease) after infliximab therapy: relationships with variations in cytokine levels in suction blister fluids.
abstract: Subcorneal pustular dermatosis (SCPD) is an uncommon disorder, characterized by a chronic relapsing vesiculopustular eruption, mainly involving the trunk and intertriginous areas, and usually seen in women > 40 years old. Various therapies have been reported to be effective in treating SCPD, such as dapsone, systemic glucocorticoids, acitretin, etretinate, infliximab and phototherapy. We report a case of a 54-year-old woman affected by SCPD who after failure of different therapies showed a dramatic but only temporary improvement of her disease during a cycle of therapy with infliximab. In addition, an array of cytokines was simultaneously measured in suction blister fluids obtained from involved or uninvolved skin at various time intervals during the first 12 weeks of observation.
authors.affiliation: Department of Dermatology, Institute S. Gallicano, Rome, Italy. bonifaticlaudio@tin.it
authors.forename: C
authors.initials: C
authors.lastname: Bonifati
authors.forename: E
authors.initials: E
authors.lastname: Trento
authors.forename: P
authors.initials: P
authors.lastname: Cordiali Fei
authors.forename: L
authors.initials: L
authors.lastname: Muscardin
authors.forename: A
authors.initials: A
authors.lastname: Amantea
authors.forename: M
authors.initials: M
authors.lastname: Carducci
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001768:Blister / Q000378:metabolism*; D001826:Body Fluids / Q000378:metabolism; D016207:Cytokines / Q000378:metabolism*; D003879:Dermatologic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D000069285:Infliximab; D008875:Middle Aged; D012872:Skin Diseases, Vesiculobullous / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000911:Antibodies, Monoclonal; D016207:Cytokines; D003879:Dermatologic Agents; D000069285:Infliximab